Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 32,692	$ 35,041
Prepaid expenses and other	1,503	1,168
Total current assets	34,471	37,171
Equipment, net	3,039	2,882
Deposits and other	1,558	1,613
Total assets	39,068	41,666
Current liabilities:
Accrued compensation and related benefits	872	773
Accrued clinical trial related costs	1,106	1,160
Accrued expenses and other	859	723
Total current liabilities	14,620	12,837
Other long-term liabilities	102	220
Stockholders’ equity:
Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at March 31, 2020 and December 31, 2019	0	0
Common stock, $0.001 par value; 300,000,000 shares authorized, and 170,770,089 and 159,791,585 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	171	160
Additional paid-in capital	459,145	440,735
Accumulated deficit	(433,268)	(417,624)
Total stockholders’ equity	19,008	23,271
Total liabilities and stockholders’ equity	39,068	41,666
Consolidated entity excluding, related party
Current assets:
Accounts receivable	17	17
Current liabilities:
Accounts payable	10,650	9,048
Healios
Current assets:
Accounts receivable	259	945
Current liabilities:
Accounts payable	1,068	1,068
Deferred revenue	65	65
Advance from Healios	5,338	5,338
Stockholders’ equity:
Stock subscription receivable from Healios	$ (7,040)	$ 0